Using DNA technology and artificial intelligence to detect diseases and create targeted treatments
Official title: DNA nanotechnology and synthetic biology for AI-supported detection and precision therapeutics
Funded at State University of New York at Albany · NIH-11009705 · Data updated 2026-11-12
This study is working on new ways to quickly and accurately find germs that make people sick and to create better treatments using cutting-edge technology, so patients can get more effective and personalized care.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Albany NIH-funded |
| Lab location | 1 site (Albany, United States) |
| Project start | January 1, 2025 |
| Project end | December 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $389,653 |
| NIH project number | 1R35GM156250-01 |
| Project ID | NIH-11009705 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with infections caused by antibiotic-resistant bacteria or those requiring precise therapeutic interventions.
✕Less likely to help
Patients with non-infectious conditions or those not affected by antibiotic resistance may not receive benefits from this research.
What this research studies
This research focuses on developing advanced methods for detecting pathogens and creating precise therapeutics using DNA nanotechnology and synthetic biology. By integrating artificial intelligence, the project aims to enhance biosensing capabilities, allowing for highly sensitive detection of various bacteria and viruses. The approach includes innovative techniques such as synthetic biology cascade reactions and CRISPR technology to identify pathogens through visual indicators. Patients may benefit from improved diagnostic tools and targeted treatments that are more effective and personalized.
Why it matters
Potential benefit: If successful, this research could lead to more accurate and timely detection of infections, as well as tailored therapies that improve patient outcomes.
How similar studies have gone: Previous research has shown promise in using DNA nanotechnology and AI for biosensing, indicating potential for success in this innovative approach.
Where this research is happening
-
State University of New York at Albany
Albany, United States Active
Researchers
- Principal investigator: Yigit, Mehmet Veysel — State University of New York at Albany
- Study coordinator: Yigit, Mehmet Veysel
Related research
Other NIH-funded projects on the same topics.
-
Cross-disease small molecule therapy for CAG expansion spinocerebellar ataxias
A new NIH grant is exploring whether existing and natural small molecules can lower harmful CAG RNA and proteins across several spinocerebellar ataxias to help people with these conditions.
-
New small molecule therapeutics to help myotonic dystrophy
A new NIH-funded project tests specially designed small molecules to lower harmful RNA activity in myotonic dystrophy and related diseases, aiming to reduce disease-driving RNA effects.
-
Biofilm structure and its role in the start of gum disease
A researchers team will study how tiny communities of bacteria at the gumline interact with the mouth’s tissues to spark inflammation that leads from healthy gums to periodontal disease.
-
Understanding how unusual RNA translation happens in neurological diseases
Researchers are studying how RNAs can start making proteins in unexpected ways in neurodegenerative diseases, which could reveal new targets for therapy.
-
Early-life neighborhood redlining and lifetime mortality in a historical cohort
This project looks at whether growing up in areas graded or disinvested by HOLC in the 1930s affects mortality later in life for people born in 1930–1940.
-
Activating PTP1B and Other Phosphatases with Small Molecules
A safety-focused, patient-friendly look at a project that aims to turn on natural enzymes in our cells to help correct harmful signals in diseases.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.